TY  - BOOK
AU  - Swain, Sandra M
TI  - Targeting HER2-positive breast cancer: advances and future directions. [Review]
SN  - 1474-1776
PY  - 2022///
KW  - IN PROCESS -- NOT YET INDEXED
KW  - Associate Dean for Research Development
KW  - MedStar Health
KW  - Journal Article
KW  - Review
N2  - The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug - the monoclonal antibody trastuzumab - almost 25 years ago. Since then, progress has been swift and the impressive clinical activity across multiple trials with monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates that target HER2 has spawned extensive efforts to develop newer platforms and more targeted therapies. This Review discusses the current standards of care for HER2-positive breast cancer, mechanisms of resistance to HER2-targeted therapy and new therapeutic approaches and agents, including strategies to harness the immune system. Copyright © 2022. Springer Nature Limited
UR  - https://dx.doi.org/10.1038/s41573-022-00579-0
ER  -